Penumbra (PEN) Cash from Financing Activities (2014 - 2026)
Penumbra (PEN) posted quarterly Cash from Financing Activities of $9.0 million for Q2 2026, down 39.09% year-over-year from $14.8 million in Q2 2025, and up 573.26% quarter-over-quarter from -$1.9 million in Q1 2026.
Penumbra (PEN) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Cash from Financing Activities for 13 consecutive years, with $9.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 39.09% year-over-year to $9.0 million; the TTM figure through Jun 2026 stood at $16.1 million (up 120.95% YoY), while the FY2025 annual figure was $26.5 million, up 130.49% from the prior year.
- Cash from Financing Activities climbed to $9.0 million in Q2 2026 per PEN's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $14.8 million in Q2 2025 and bottomed at -$100.6 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged -$1.4 million across 5 years, with a median of $4.5 million in 2025.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 47531.13% — and 2025, when it surged 441.06%.
- Penumbra's Cash from Financing Activities stood at $5.7 million in 2022, then increased by 3.24% to $5.9 million in 2023, then advanced by 2.48% to $6.1 million in 2024, then fell by 16.66% to $5.1 million in 2025, then jumped by 78.47% to $9.0 million in 2026.
- Business Quant data shows PEN's Cash from Financing Activities at $9.0 million in Q2 2026, -$1.9 million in Q1 2026, and $5.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Penumbra | 12.76 Bn | 12.10 Bn | 264.94 Mn | 9.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.03 Mn |
| Jun 30, 2026 | 9.03 Mn |
| Mar 31, 2026 | -1.91 Mn |
| Mar 31, 2026 | -1.91 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Jun 30, 2025 | 14.82 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Sep 30, 2024 | -100.55 Mn |
| Jun 30, 2024 | 8.27 Mn |
| Jun 30, 2024 | 8.27 Mn |
| Mar 31, 2024 | -794,000.00 |
| Mar 31, 2024 | -794,000.00 |